INVESTORS CONTACT US ABOUT US OUR SCIENCE OUR PIPELINE RESOURCES JOIN US RESOURCES INFORMATIVE RESOURCES Take a look at the latest on Palatin across our media publications, posters, and presentations. All Indications Cardiovascular (4) Female Sexual Dysfunction (32) Inflammatory and Autoimmune (4) Obesity and Diabetes (0) Ocular (8) All Resources Abstract (1) Poster (28) Presentation (5) Publication (12) Webcast (2) DED TREATMENTS ON THE HORIZON:TOLERABILITY AND EFFICACY OF THE MELANOCORTIN AGONIST PL9643 2021-December Positive results were seen across multiple signs and symptoms of dry eye disease (DED) in a phase 2 study of Palatin Technologies’ MCR pan-agonist, PL9643, in adults with mild, moderate, or severe DED. Continued development of PL9643 as a novel therapy for DED is supported by a planned phase 3 trial comparing PL9643 to vehicle in more than 300 patients with moderate to severe DED. The Melanocortin Pathway: A New Target For Ocular Disease Therapy 2021-October Therapeutically targeting the melanocortin pathway represents a novel approach to the treatment of ocular diseases. Synthetic MCr receptor agonists show promise in the treatment of uveitis and retinopathy in preclinical animal models and PL9643 has demonstrated efficacy in treating signs and symptoms of dry eye disease in humans. Protective Effects Of Two Melanocortin Agonists Delivered By Intravitreal Injection In Mouse Models Of Retinopathy 2021-September Melanocortin agonists have demonstrated anti-inflammatory effects in various experimental models of inflammatory disease. PL8331 and PL9654 are melanocortin 1 receptor agonists being evaluated preclinically for the treatment of various ocular diseases. Probing The Role Of The Melanocortin Receptor Agonists In Experimental Immune-Mediated Diseases 2021-September Effect Of The Melanocortin Receptor Agonist PL8177 On DSS-Induced Colitis In Rats And A Toxicologic Assessment Of PL8177 In Beagle Dogs 2021-September Efficacy And Safety Of The Melanocortin Agonist PL9643 In A Phase 2 Study Of Subjects With Dry Eye Disease 2021-July The Role Of The Melanocortin Agonists In Ocular Indications 2021-May Investor’S Day Presentation 2021-May Melanocortin Agonists for Ocular Diseases Protective Effects Of 2 Melanocortin Agonists Delivered By Intravitreal Injection In Mouse Models Of Retinopathy 2021-May Melanocortins have a wide range of activities, including inhibition of leukocyte activation, inhibition of inflammation, and protection of tissues1-3 The melanocortin system plays a key role in promoting resolution of the inflammatory process Efficacy And Safety Of The Melanocortin Agonist PL9643 In A Phase 2 Study Of Subjects With Dry Eye Disease 2021-May This is a multifactorial inflammatory disease affecting multiple areas in the eye. Existing therapies are often inadequate due to poor efficacy, adverse effects, or poor tolerability. 4-B Cedar Brook Drive Cedar Brook Corporate Center Cranbury, NJ 08512 © 2021 PALATIN | ALL RIGHTS RESERVED | PRIVACY POLICY | TERMS OF USE | ACCESSIBILITY STATEMENT